1785764-26-2

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Diamino-1,3-diethyluracil Hydrochloride is used as an anticonvulsant medication for the treatment of epilepsy and seizure disorders. It is effective in reducing the frequency and severity of seizures by modulating the voltage-gated sodium channels in the brain, thereby stabilizing the abnormal electrical activity.
Used in Epilepsy Management:
5,6-Diamino-1,3-diethyluracil Hydrochloride is used as a therapeutic agent in epilepsy management, where it plays a crucial role in controlling seizures. It is often prescribed by healthcare professionals and administered orally in the form of tablets or capsules to ensure patient compliance and effectiveness.
Used in Treatment of Other Seizure Disorders:
Beyond epilepsy, 5,6-Diamino-1,3-diethyluracil Hydrochloride is also utilized as a treatment for other types of seizure disorders. Its ability to modulate voltage-gated sodium channels makes it a valuable asset in managing various conditions characterized by abnormal electrical brain activity.

Upstream product

• 22390-04-1 1,3-diethyluracil 
• 89073-60-9 6-amino-1,3-diethyl-5-nitroso-1H,3H-pyrimidine-2,4-dione 

Downstream Products

• 155271-84-4 (E)-8-(3-bromostyryl)-1,3-diethyl-1H-purine-2,6(3H,7H)-dione 

Relevant academic research and scientific papers

Novel preparation method for Istradefylline

The invention relates to a preparation method for Istradefylline represented by a formula (I) shown in the description. The method comprises the following steps: subjecting 6-amino-1,3-diethyl-5-nitroso-1H-pyrimid-2,4-dione represented by a formula (II) shown in the description, which serves as a raw material, to catalytic reduction and salt forming, so as to obtain 5,6-diamino-1,3-diethyl-1H-pyrimid-2,4-dione hydrochloride represented by a formula (III) shown in the description; then, carrying out acetylation on the compound (III), so as to obtain N-(6-amino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimid-5-yl)acetamide represented by a formula (IV) shown in the description; carrying out further ring closing, so as to obtain 1,3-diethyl-8-methyl-1H-purin-2,6(3H,7H)-dione represented by a formula (V) shown in the description; and carrying out methylation on the compound (V) firstly, and then, subjecting the methylation product to a condensation reaction with veratraldehyde represented by a formula (VII) shown in the description, thereby obtaining the end product Istradefylline. According to the novel preparation method for the Istradefylline, provided by the invention, raw materials, which are readily available industrially and are low in price, are used, the production process is more environmentally friendly, and the obtained product Istradefylline is high in yield and purity, thereby having a relatively high practical value.

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

Adenosine receptor antagonists that are selective for the A2A receptor subtype (A2A antagonists) are under investigation as possible therapeutic agents for the symptomatic treatment of the motor deficits associated with Parkinson's disease (PD). Results of recent studies in the MPTP mouse model of PD suggest that A2A antagonists may possess neuroprotective properties. Since monoamine oxidase B (MAO-B) inhibitors also enhance motor function and reduce MPTP neurotoxicity, we have examined the MAO-B inhibiting properties of several A2A antagonists and structurally related compounds in an effort to determine if inhibition of MAO-B may contribute to the observed neuroprotection. The results of these studies have established that all of the (E)-8-styrylxanthinyl derived A2A antagonists examined display significant MAO-B inhibitory properties in vitro with Ki values in the low μM to nM range. Included in this series is (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KW-6002), a potent A2A antagonist and neuroprotective agent that is in clinical trials. The results of these studies suggest that MAO-B inhibition may contribute to the neuroprotective potential of A2A receptor antagonists such as KW-6002 and open the possibility of designing dual targeting drugs that may have enhanced therapeutic potential in the treatment of PD.